Pulmonx Corp Ordinary Shares LUNG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LUNG is a good fit for your portfolio.
News
-
Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024
-
Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer
-
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial
-
Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results
-
Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer
-
Pulmonx to Report Fourth Quarter and Full Year 2023 Financial Results on February 21, 2024
Trading Information
- Previous Close Price
- $7.30
- Day Range
- $7.26–7.50
- 52-Week Range
- $7.11–14.84
- Bid/Ask
- $7.27 / $7.29
- Market Cap
- $282.55 Mil
- Volume/Avg
- 388,074 / 591,964
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.03
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 279
- Website
- https://www.pulmonx.com
Comparables
Valuation
|
Metric
|
LUNG
|
ATEC
|
EMBC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 3.27 |
Price/Book Value | 2.37 | 22.71 | — |
Price/Sales | 4.03 | 3.20 | 0.53 |
Price/Cash Flow | — | — | 5.10 |
Price/Earnings
LUNG
ATEC
EMBC
Financial Strength
|
Metric
|
LUNG
|
ATEC
|
EMBC
|
|---|---|---|---|
Quick Ratio | 5.62 | 1.86 | 1.55 |
Current Ratio | 6.50 | 2.86 | 2.20 |
Interest Coverage | −19.37 | −10.23 | 1.59 |
Quick Ratio
LUNG
ATEC
EMBC
Profitability
|
Metric
|
LUNG
|
ATEC
|
EMBC
|
|---|---|---|---|
Return on Assets (Normalized) | −22.61% | −9.89% | 12.52% |
Return on Equity (Normalized) | −31.80% | — | — |
Return on Invested Capital (Normalized) | −25.75% | −9.94% | 30.00% |
Return on Assets
LUNG
ATEC
EMBC
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Jzpwpkvk | Dgkfvn | $185.4 Bil | |
SYK
| Stryker Corp | Kcjpjbby | Lqdcf | $127.7 Bil | |
BSX
| Boston Scientific Corp | Bmmmvrqqr | Slwmkwf | $107.6 Bil | |
MDT
| Medtronic PLC | Xhkfgymjc | Csrxxxk | $105.9 Bil | |
DXCM
| DexCom Inc | Ftsqklsgv | Fxq | $54.7 Bil | |
EW
| Edwards Lifesciences Corp | Jgdpvykpm | Gsxpnyt | $52.0 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Fnfgxzzc | Qrvgt | $24.6 Bil | |
ALGN
| Align Technology Inc | Vqgsdvw | Pfgtb | $23.4 Bil | |
PHG
| Koninklijke Philips NV ADR | Qgwgxvyk | Qxlmyl | $18.7 Bil | |
PODD
| Insulet Corp | Grbmtcjgpc | Mcrtdg | $11.6 Bil |